First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands

1. Algernon Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Health.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

1. For the quoted article (published on March 26, 2026), Algernon Health has paid Street Smart, an affiliate of Streetwise Reports, US$3000.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) announced that it will open its inaugural brain PET scanning clinic at the HCA Florida University Medical Office Building in Davie, Florida, located on the campus of the HCA Florida University Hospital. Algernon USA LLC, a wholly owned subsidiary, has signed a five-year lease with a five-year renewal option for the site.

According to the company, the clinic will be the first location of its kind in the United States to provide brain-dedicated PET scans to aid in the detection of Alzheimer's Disease and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders, including Parkinson's disease. Brain PET scans for beta-amyloid plaque detection are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older.

The facility will feature the U.S. FDA-cleared CareMiBrain system, a standalone diagnostic PET scanner that does not require an integrated CT component. The company stated that this design results in 25% less radiation exposure for patients compared to PET/CT scanners.

Algernon noted that two U.S. FDA-approved monoclonal antibody treatments for Alzheimer's Disease, Leqembi and Kisunla, require a positive beta-amyloid brain scan or spinal tap before patients can be authorized to receive them. These treatments are also covered by Medicare, Medicaid, and private insurance.

The company stated that the current supply of PET/CT scanners is insufficient to serve demand for Alzheimer's diagnostics and treatment, noting that 45% of these scanners are located in hospitals and are primarily used for cancer diagnostics and cardiac imaging.

Christopher J. Moreau, CEO of Algernon, said in a company news release, "We are very pleased to be opening our first neuroimaging clinic in a brand-new suite at the HCA Florida University Medical Office Building. We look forward to delivering the highest level of care possible to our patients in Florida, as part of a professional healthcare community that is dedicated to medical excellence."

Algernon previously announced that it had signed a definitive equipment order and financing agreement with Catalyst MedTech for four CareMiBrain systems to be installed in its first four planned clinics. The company stated that this represents a non-dilutive deal valued at over CA$4 million and includes an agreement to acquire an additional six systems for future clinics.

The flagship clinic will be located at 7630 SW 34th Manor in Davie, Florida. The company stated that the area includes a population of over 6.4 million people within a 60-mile radius, including 2.5 million people aged 50 and over.

Algernon Health Inc. also announced on March 25 that it has introduced NOVASCAN NEUROIMAGING CLINICS™ as the new brand name and visual identity for its planned U.S. network of brain PET scanning centers. The branding will be applied to its inaugural location at the HCA Florida University Medical Office Building in Davie, which will feature the U.S. FDA-cleared CareMiBrain system, a standalone PET scanner without an integrated CT component.

The company stated that the Florida clinic will provide dedicated, brain-optimized PET scans to aid in the detection and treatment of Alzheimer's Disease by confirming the presence of beta-amyloid plaques. The facility will also be used to scan patients for other neurological conditions, including dementia, epilepsy, Parkinson's disease, multiple sclerosis, and brain cancer, and will be available for clinical trials evaluating new tracers.

According to the company, the CareMiBrain system delivers 25% less radiation exposure compared to traditional PET/CT scanners, as it does not include a CT component. The company also noted that its inaugural clinic is located approximately twenty minutes southwest of Fort Lauderdale and is being prepared for opening, with further updates expected regarding the official launch date and the commencement of patient referrals.

Christopher J. Moreau said in a company news release, "Our goal was to settle on a name and symbol that would capture the essence of what we are planning to achieve in offering a new approach to dedicated brain PET scanning as an important component of the healthcare system."

Advancing Alzheimer's Detection Through Biomarkers, Diagnostics, and Early Care Initiatives

Research published March 23 by Lund University highlighted the growing role of biomarkers in identifying Alzheimer's disease well before symptoms appear. According to the study, "signs of Alzheimer's in the brain can be detected in the blood up to 20 years before symptoms become apparent," reflecting a shift toward earlier-stage detection. The research also addressed limitations in existing methods, noting that "a blood marker can sometimes produce a positive result in people who do not yet meet the criteria for the disease," with false-positive results observed in 43 per cent of cases with elevated p-tau217 levels.

By combining biomarkers, the researchers stated that "we can better identify which people have Alzheimer's disease and which of them have such an advanced stage of the disease that it leads to symptoms," while reducing false positives and improving diagnostic accuracy.

Developments in blood-based diagnostic tools were also reported by CLP on March 23 in coverage of new immunoassay technologies targeting neurodegenerative biomarkers. According to that report, new assays were designed to detect Alzheimer's-related tau changes "at the preclinical stage," supporting earlier identification of disease processes. The same report noted that clinical guidelines had begun incorporating these tools, stating that the Alzheimer's Association had recommended blood-based biomarker tests, including plasma p-tau217, as "triaging and confirmatory tools in patients with objective cognitive impairment," with specified sensitivity and specificity thresholds for clinical use.

Feng Xuan, founder and chief executive officer of a company developing such assays, stated in a release, "Our goal is to place the most sensitive protein biomarker tools in the hands of scientists tackling complex neurodegenerative diseases," while Oliver Tassinari added that the technology enabled "richer data from more assays without depleting samples."

Policy and healthcare system initiatives were also addressing diagnostic capacity and access. A March 23 announcement from U.S. lawmakers introduced legislation aimed at improving provider training for dementia detection and care. According to the release, the proposed legislation would "improve detection, diagnosis, and treatment of Alzheimer's, as well as other forms of dementia" through expanded training opportunities.

Senator Amy Klobuchar stated that "detecting Alzheimer's and other dementias early can reduce stress for patients and families, lower unnecessary health costs, and improve access to care," while Rachel Conant of the Alzheimer's Association noted that "delays in diagnosis often mean missed opportunities for care, planning and support," emphasizing the role of earlier identification within community-based healthcare settings.

Technical Analyst Highlights Alzheimer's Diagnostic Strategy and Assigns Speculative Buy Rating

¹According to a March 26 report from Stewart Thomson, Algernon Health Inc. was described as "a Canadian healthcare company," with a strategic focus on Alzheimer's diagnostics using brain-optimized PET imaging. The report stated that "this plan will make the company's main business diagnosing Alzheimer's disease, using high-technology brain-optimized Positron Emission Tomography (PET) scans for diagnosis," and referenced "the goal of capturing a US$6.9 billion emerging market."

Thomson also wrote on March 26 that "the company is entering the Alzheimer's Disease (AD) diagnostic market segment with plans to establish a network of dedicated neuroimaging medical clinics in the U.S.," adding that the clinics would utilize "the most advanced, FDA-cleared brain-specific PET scanner to focus on early-stage detection of the disease."

In the same report, Thomson assigned a "Technical Rating: Strong Speculative Buy" to the company and outlined price targets of "CA$0.08" in the short term, "CA$0.17" in the medium term, and "CA$0.40" in the long term.

U.S. Clinic Rollout, Equipment Deployment, and Brain Specific PET Scanning Expansion

The company stated in its investor presentation that it plans to open multiple neuroimaging clinics across the United States, beginning with its flagship location in Davie, Florida.

Algernon also indicated that it intends to work in partnership with neurologists, geriatricians, primary care physicians, and other healthcare providers to generate patient referrals, while also marketing directly to the population aged 50 and over to promote early detection through cognitive testing, blood biomarker testing, and brain PET scans.

In support of its clinic rollout, the company has entered into a supply, financing, and services agreement valued at approximately CA$4 million for the delivery of four U.S. FDA-cleared CareMiBrain systems for its initial clinics, with an additional agreement to acquire up to six more systems for future locations.

The investor presentation also outlined partnerships with a U.S.-based provider of molecular imaging and nuclear medicine technology, which will supply equipment and provide regulatory, licensing, and clinical support services for the planned clinic network. 

Additionally, the company noted the potential for a future NASDAQ listing as part of its broader corporate strategy.

Ownership and Share Structure²

Management and insiders own about 11% of the company, and about 21% is owned by institutions. The rest is with retail.

Top shareholders include Alpha North Asset Management with 20.52%, Chief Executive Officer Christopher Moreau with 5.05%, Chairman of the Board Harry Bloomfield with 1.97%, and Chief Financial Officer James Kinley with 1.4%, and Director Rajpaul Attariwala with 1.2%.

Algernon has 54.1 million outstanding shares, a market cap of US$1.37 million, and a 52-week range of US$0.035 - US$0.10.